The Human Vaccines Project

Decoding the Human Immune System

Mission

Established in 2016, the Human Vaccines Project is a global, non-profit, public-private partnership, operating as a human immunology-based clinical research consortium with the mission to “Decode the human immune system, to accelerate development of vaccines and therapies for major global diseases.”

Ruling year info

2015

Founding President and CEO

Wayne Koff

Co-Founder and COO

Ted Schenkelberg

Main address

1 PENN PLAZA NO 6178

NEW YORK, NY 10119 USA

Show more contact info

EIN

47-2364966

NTEE code info

Research Institutes and/or Public Policy Analysis (H05)

IRS filing requirement

This organization is required to file an IRS Form 990 or 990-EZ.

Sign in or create an account to view Form(s) 990 for 2019, 2018 and 2017.
Register now

Communication

Programs and results

What we aim to solve

This profile needs more info.

If it is your nonprofit, add a problem overview.

Login and update

Our programs

SOURCE: Self-reported by organization

What are the organization's current programs, how do they measure success, and who do the programs serve?

The Newborn Immunity Initiative

Globally, each year 3 million children are born stillborn, another 15 million babies are born dangerously pre-term, and 800,000 newborns die from infection. The Newborn Immunity Initiative will reduce infant mortality by determining the functional molecular drivers of maternal-fetal immune interactions. The Newborn Immunity Initiative aims to identify how the maternal immune baseline predicts the immune trajectory of a mother's offspring and the accompanying risk for stillbirth, neonatal and infant infections, and the neonatal and infant vaccine response. In conjunction with this, the Newborn Immunity Initiative will also examine how currently licensed vaccines given to the mother affect the immune trajectory of her offspring. This initiative brings together partners at the Telethon Kids Institute, Université Libre in Brussels, and Cincinnati Children's Hospital.

Population(s) Served
Infants and toddlers
Children
Families
Parents

The Human Immunomics Initiative (HII) is a joint initiative partnering the Harvard T.H. Chan School of Public Health and the Human Vaccines Project to create the world’s premier immunology initiative that aims to revolutionize the understanding of the human immune system and accelerate the creation of effective vaccines, with a specific focus on aging populations. The HII will merge large-scale cohort studies with advances in systems biology, bioinformatics, and artificial intelligence (AI) to determine the rules of engagement for effective immunity in aging populations aiming to answer core questions of aging such as: Why do some people get disease as they age, while others do not? And how do we engineer aging immune systems to better fight disease?

Population(s) Served
Older adults
Seniors

The COVID Vaccine Initiative (CVI) aims to ensure the development of safe, effective, and accessible vaccines for those most vulnerable to COVID-19: aging populations and those living in low- and middle-income countries. It leverages HVP’s global clinical research consortium, including collaborations with the Harvard T.H. Chan School of Public Health focused on deciphering effective immunity in aging populations; FHI 360, a global nonprofit research and human development organization with extensive experience working in low and middle-income countries; and the University of Minnesota’s Center for Infectious Disease Research and Policy, a global leader in addressing public health preparedness and emerging infectious disease response. The CVI will facilitate efforts of the global community to efficiently generate key information critical to accelerating development of safe and effective vaccines against COVID-19 while providing a global blueprint for future pandemic preparedness for emerging infectious diseases.

Population(s) Served
Older adults
Seniors
Ethnic and racial groups
Social and economic status

Where we work

Our Sustainable Development Goals

SOURCE: Self-reported by organization

Learn more about Sustainable Development Goals.

Goals & Strategy

SOURCE: Self-reported by organization

Learn about the organization's key goals, strategies, capabilities, and progress.

Charting impact

Four powerful questions that require reflection about what really matters - results.

At the Human Vaccines Project, we aim to transform the future of human health by decoding the human immune system. By gaining a complete understanding of the immune system, we can more effectively and expeditiously fight both non-communicable and infectious diseases - accelerating the development of vaccines, treatments, and therapies for all people.

In the past decades, huge advances in genomics and bioinformatics make it now possible to decode the human immune system for the first time. Our scientific plan focuses on two areas:

1. Understanding the rules and components of immunity
2. Creating AI-driven models of immunity

Through numerous initiatives, studies, and partnerships focused on examining different aspects of human immunity, we seek to understand the immune system as a whole and harness its extraordinary disease-fighting power.

By creating the world’s largest immunology-based research network we have the ability to foster research and collaboration among leading scientists, institutions, and governments around the globe. Through our global consortium we enable leading researchers and scientists around the world to work together in designing, implementing, and analyzing outputs from scientific studies. We also partner with leading academic institutions to study specific aspects of immunity and ensure comprehensive data analytics and management.

In the first three years, we have open-sourced the first sequencing of the human immune system, used machine learning to predict who will and will not respond to vaccination, and established one of the world's leading scientific consortiums and immunology-based research networks. Our network has published several peer-reviewed publications in high-profile journals, and we’ve made our data publicly available for additional research.

Financials

The Human Vaccines Project
lock

Unlock financial insights by subscribing to our monthly plan.

Subscribe

Unlock nonprofit financial insights that will help you make more informed decisions. Try our monthly plan today.

  • Analyze a variety of pre-calculated financial metrics
  • Access beautifully interactive analysis and comparison tools
  • Compare nonprofit financials to similar organizations

Want to see how you can enhance your nonprofit research and unlock more insights?
Learn more about GuideStar Pro.

Operations

The people, governance practices, and partners that make the organization tick.

lock

Connect with nonprofit leaders

Subscribe

Build relationships with key people who manage and lead nonprofit organizations with GuideStar Pro. Try a low commitment monthly plan today.

  • Analyze a variety of pre-calculated financial metrics
  • Access beautifully interactive analysis and comparison tools
  • Compare nonprofit financials to similar organizations

Want to see how you can enhance your nonprofit research and unlock more insights? Learn More about GuideStar Pro.

lock

Connect with nonprofit leaders

Subscribe

Build relationships with key people who manage and lead nonprofit organizations with GuideStar Pro. Try a low commitment monthly plan today.

  • Analyze a variety of pre-calculated financial metrics
  • Access beautifully interactive analysis and comparison tools
  • Compare nonprofit financials to similar organizations

Want to see how you can enhance your nonprofit research and unlock more insights? Learn More about GuideStar Pro.

The Human Vaccines Project

Board of directors
as of 2/12/2021
SOURCE: Self-reported by organization
Board chair

Ian Gust

Organizational demographics

SOURCE: Self-reported; last updated 02/11/2021

Who works and leads organizations that serve our diverse communities? GuideStar partnered on this section with CHANGE Philanthropy and Equity in the Center.

Leadership

The organization's leader identifies as:

Race & ethnicity
White/Caucasian/European

The organization's co-leader identifies as:

Race & ethnicity
White/Caucasian/European

Race & ethnicity

No data

Gender identity

No data

 

No data

Sexual orientation

No data

Disability

No data